Full-Time

Clinical Research Program Manager

MCRS Strategic Account Manager

Posted on 9/9/2026

Deadline 9/30/26
Medtronic

Medtronic

10,001+ employees

Medical device maker advancing therapies

Compensation Overview

$132.8k - $199.2k/yr

No H1B Sponsorship

Minneapolis, MN, USA

Remote

The position can be based anywhere globally; local return-to-office requirements may apply.

Bachelor's, Master's, MBA

Category
Sales & Account Management (1)
Required Skills
Forecasting
Risk Management
Data Analysis

Get referred to Medtronic

See people who can refer or advise you

Requirements
  • A bachelor's degree.
  • At least 5 years of related clinical experience, or at least 3 years with an advanced degree.
  • Experience in clinical research, clinical operations, strategic account management, business development, or portfolio management within healthcare, medical device, pharmaceutical, contract research organization, or related life sciences organizations.
  • Experience building and influencing relationships across complex, global matrix organizations and leading strategic customer or business partner engagements.
  • Knowledge of clinical trials, evidence generation, regulatory requirements, quality systems, and compliance processes.
  • Experience managing business performance, including budgets, forecasting, proposals, contracts, vendor oversight, and portfolio-level planning.
  • For baccalaureate degrees earned outside the United States, a degree satisfying the requirements of 8 C.F.R. § 214.2(h)(4)(iii)(A) is required.
  • Candidates for roles below the Principal level must possess unrestricted U.S. work authorization at the time of hire and for the duration of employment.
Responsibilities
  • Serve as the primary contact for operating-unit and regional leaders and MCRS stakeholders, ensuring their needs are met and building partnerships.
  • Promote internal collaboration with MCRS teams to drive organizational growth.
  • Lead and enhance engagement activities with operating-unit and regional partners, building relationships and developing insights into trends, service gaps, industry priorities, and market pressures.
  • Collaborate across MCRS teams to deliver customized solutions addressing evolving stakeholder needs.
  • Identify new opportunities for clinical evidence generation.
  • Facilitate strategic discussions with operating-unit and regional partners and MCRS to anticipate future needs and challenges.
  • Act as a reference point for service capabilities, pipeline commissioning, and new business opportunities.
  • Assess and communicate the value of new or modified services through pilot programs and educate partners on current and future offerings.
  • Generate new leads through networking and outreach.
  • Manage service offerings, track progress, and analyze customer needs to deliver tailored solutions.
  • Oversee the proposal and negotiation process for MCRS services, including potential outsourcing, while aligning expectations and deliverables.
  • Develop and execute strategic plans with operating-unit and regional partners using data analysis, benchmarking, and market intelligence.
  • Support ongoing market intelligence and competitive analysis.
  • Oversee portfolio-level deliverables and timelines, ensuring alignment with objectives and budget.
  • Provide regular updates on performance, quality, and financial status, including insights into cost and performance drivers.
  • Apply lessons learned to drive continuous improvement with MCRS and operating-unit stakeholders.
  • Conduct service delivery performance reviews and provide constructive feedback.
  • Work with finance partners to ensure accurate forecasting and ongoing financial oversight of the portfolio.
  • Identify and mitigate portfolio-level risks with MCRS stakeholders.
  • Collaborate with Quality and Compliance teams on regulatory requirements and quality and compliance concerns.
  • Lead end-to-end issue resolution by diagnosing root causes and implementing effective solutions.
  • Ensure communication, escalation, and resolution of risks and issues related to quality, safety, timelines, and budget.
  • Capture and share best practices to prevent risks across the portfolio.
  • Provide leadership for the conduct of clinical studies and the regulatory affairs function as it applies to product approval.
  • Ensure studies are scientifically valid, meet relevant regulatory requirements, and are conducted within ethical guidelines.
  • Ensure clinical studies fairly assess the safety and efficacy of tested products and support timely product approvals.
  • Develop and implement regulatory strategies to obtain timely product approvals from worldwide regulatory bodies.
  • Ensure regulatory submissions are accurately prepared and comply with regulatory approvals.
  • Represent Medtronic’s clinical research function within the country or region and collect feedback from local customers and authorities.
  • Build and maintain networks and relationships with internal and external parties.
  • Lead execution of local and global studies and manage clinical research projects across Medtronic therapies and businesses.
Desired Qualifications
  • An advanced degree, specifically an MBA or master's degree, or a relevant certification such as PMP.
  • Experience developing business cases, growth strategies, or market assessments.

Medtronic makes medical devices and therapies to treat chronic diseases, including implantables, sensors, and diabetes management tools. Its devices interact with the body to regulate or monitor functions, such as pacemakers delivering heart stimulation and neuromodulation devices sending electrical signals. The company differentiates itself through a long history of device development and a broad portfolio, expanded via acquisitions to access new technologies and markets. Its goal is to improve patient health outcomes by providing integrated medical technologies that help manage chronic conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Fridley, Minnesota

Founded

1949

Get referred to Medtronic

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 fiscal 2027 revenue reached $9.756 billion, with 13.7% organic growth on September 1.
  • Cardiac Ablation Solutions surged 88%, and Affera reached $2 billion trailing revenue.
  • Pi-Cardia and Cornerstone deepen structural heart and robotics, both strong September 2026 moves.

What critics are saying

  • FDA flagged Medtronic's Bravo pH capsule recall on August 27, 2026 after 184 injuries.
  • A repeat recall in two years destroys trust in Medtronic's post-market surveillance systems.
  • MiniMed separation remains unfinished; execution slips through fiscal 2027 would distract management and valuation.

What makes Medtronic unique

  • Medtronic spans cardiovascular, neuroscience, and surgical robotics across 150 countries.
  • Hugo and Cornerstone Sentire give Medtronic a two-platform robotic surgery portfolio outside the U.S.
  • MiniMed separation preserves a focused diabetes franchise while Medtronic concentrates capital on higher-growth devices.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Employee Assistance Program

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Medical Device Network
Sep 4th, 2026
Boston Scientific's SCS leads linked to 1,081 serious injuries in FDA alert.

Boston Scientific's SCS leads linked to 1,081 serious injuries in FDA alert. Boston's recall comes at a time where several players in the medtech industry are facing personal injury lawsuits over SCS system malfunctions. The US Food and Drug Administration (FDA) has issued an alert over Boston Scientific's recall of a lead kit used with its spinal cord stimulator (SCS) system at a time when the company and other medtech industry players are facing lawsuits over SCS systems malfunctioning. In a letter sent to customers on 17 June, Boston said the body of its Infinion CX leads, which are compatible with its SCS systems for relieving chronic pain in the back and limbs, including Spectra WaveWriter and WaveWriter Alpha, may experience "mechanical stress at the anchor site", an issue that may result in high impedance measurements or lead fractures. These abnormal impedance measurements may lead to inadequate stimulation and/or additional intervention, including lead explant and replacement, the company stated as per the FDA alert. SCS is a form of neuromodulation used for treating chronic, severe nerve pain in the trunk, arms, or legs when conservative treatments have failed. As of 27 May, Boston Scientific has reported 1,081 serious injuries and no deaths associated with this issue. While the action does not affect SCS devices that have already been implanted, Boston now recommends that all unused Infinion CX leads be removed from where they are used or sold. Boston's recall comes at a time in which the company, alongside other players in the medtech industry with SCS systems, including Medtronic and Abbott, are facing lawsuits regarding device failure, shocks, and lack of pain relief. A series of lawsuits pertaining to Boston's SCS systems were formally centralised into a single federal multidistrict litigation (MDL) on 5 June 2026 for coordinated proceedings. Meanwhile, in August 2026, Abbott opposed the creation of a proposed MDL seeking to consolidate 23 personal injury lawsuits involving its SCS systems into a single proceeding in the Central District of California. According to GlobalData analysis, the global neurology devices market, of which SCS systems are a part, is projected to reach a valuation above $25bn in 2034. Meanwhile, a recent report from GlobalData forecasts that the SCS market will be worth $3.5bn in North America in 2033. Give your business an edge with its leading industry insights.

Today's Medical Developments
Sep 4th, 2026
Medtronic announces partnerships, investments with Cornerstone Robotics and Pi-Cardia.

Medtronic announces partnerships, investments with Cornerstone Robotics and Pi-Cardia. The medtech company will gain access to surgical robotics and structural heart technology through the agreements. Published September 04, 2026 Medtronic announced a strategic partnership with Cornerstone Robotics, an innovative surgical robotics company committed to advancing minimally invasive surgery and improving access to the latest surgical care worldwide. The approximately $700 million investment includes rights to distribute Cornerstone Robotics' Sentire surgical system in select markets outside the U.S. where the system is market approved. Medtronic will distribute Sentire alongside its Hugo robotic-assisted surgery (RAS) system. Together with Medtronic's connected surgical ecosystem, the two complementary platforms will expand access to robotic-assisted surgery and offer surgeons and health systems more choice and flexible solutions designed to meet their diverse needs and reach more patients globally. With global adoption of robotic-assisted surgery still in the single digits, the opportunity to expand access to advanced surgical care for patients, physicians, and health systems around the world is significant. Expanded choice and access are critical drivers of the future of robotic assisted surgery. Through this partnership, Medtronic and Cornerstone Robotics are building a multi-port portfolio anchored by the Hugo RAS system and expanded by Sentire, giving customers meaningful flexibility across clinical settings, procedural needs, and economic models. "Our strategy is focused on driving the next generation of minimally invasive surgery, one of our biggest growth opportunities," says Matt Anderson, senior vice president and president, Surgical, Medtronic. "Surgeons, health systems and markets have varying needs and preferences, which is why we are investing across robotic platforms, digital tools, and platform-enhancing technologies. With Sentire complementing the Hugo RAS system, Medtronic will be the only company offering this two-platform portfolio combined with our surgical ecosystem - giving customers more access, more choice, and flexible solutions that fit their clinical and operational needs." Building on Hugo's momentum. The partnership builds on the momentum of Medtronic's Hugo RAS system, which is now being used in more than 35 countries across six continents, including the United States, where it received FDA clearance within the last year. Procedure growth for the Hugo RAS system is currently more than 2x the growth rate of the robotic surgery market, and total procedures are expected to exceed 50,000 globally by the end of Medtronic's fiscal year. Medtronic will continue to innovate the capabilities of the Hugo RAS system, including ongoing software upgrades, real-time artificial intelligence across its digital ecosystem, integrated stapling, expanded instrumentation, and clinical indications. The modular, multi-quadrant platform is designed for a broad range of soft-tissue surgical procedures and combines wristed instruments, 3D visualization, and Touch Surgery ecosystem with dedicated support for robotics program optimization, service, and training. Expanding access through Sentire surgical system. The Sentire system's architecture and immersive console with dual-console capability offer a familiar configuration suited to varying surgeon preferences and clinical needs. Developed entirely in-house by Cornerstone Robotics, Sentire has completed multi-specialty clinical trials and received CE Mark in May 2026 for use in minimally invasive general, gynecologic, thoracic, and urologic surgical procedures in addition to its market approval in China and Singapore. "Since the founding of Cornerstone Robotics, we have been steadfast in our commitment to innovation, excellence, and clinical value," says Samuel Au, founder and CEO, Cornerstone Robotics. "We are confident physicians and patients alike will be the greatest beneficiaries of this partnership as we continue to expand access across this dynamic market." Medtronic continues to invest across its surgical ecosystem to expand access to robotic-assisted solutions for operating rooms around the world. This partnership is another step in strengthening that connected ecosystem and advancing the company's commitment to improving the lives of patients through minimally invasive surgery. Investment in Pi-Cardia. Medtronic also announced a strategic investment in Pi-Cardia Ltd., a pioneer in leaflet modification technologies for structural heart disease. With a focus on addressing the evolving needs of increasingly complex transcatheter aortic valve replacement (TAVR) patients and procedures, Medtronic secures an option for strengthening its structural heart portfolio through this strategic investment, supporting the next generation of innovation. Pi-Cardia's ShortCut device is the first FDA-cleared leaflet modification technology designed to enable valve-in-valve TAVR procedures in patients at risk of coronary obstruction. The device provides physicians with a safe, easy-to-learn, reproducible approach to leaflet modification that can help preserve coronary access and enable future transcatheter valve procedures. In FDA-reviewed clinical studies, ShortCut demonstrated successful leaflet splitting in all pivotal trial patients and a favorable safety profile. "As structural heart care evolves, we're investing in technologies that help physicians address today's challenges while preparing for tomorrow's opportunities," says Jorie Soskin, vice president and general manager of the Structural Heart business within Medtronic's Cardiovascular portfolio. "Our investment in Pi-Cardia reflects our commitment to building a portfolio of technologies that will shape the future of TAVR, particularly for patients with complex anatomy. We believe leaflet modification technologies like ShortCut have the potential to become an important component of structural heart care and the future of TAVR as transcatheter therapies continue to advance." Under the agreement, Medtronic will make strategic investments of up to $80 million into Pi-Cardia and is expected to become the exclusive global commercial distributor of the ShortCut device in 2027. Medtronic will leverage its worldwide Structural Heart organization to expand physician access across the United States, Europe, Japan, and other international markets. The agreement also includes an option for Medtronic to acquire Pi-Cardia upon achievement of predefined milestones for an estimated upfront acquisition price of up to $210 million, subject to customary adjustments, plus additional potential earn-out payments post-acquisition that could meaningfully increase the total consideration. The transactions are subject to regulatory approval and customary closing conditions. "Our mission has been to make leaflet modification a standard part of complex TAVR," says Erez Golan, chief executive officer of Pi-Cardia. "Medtronic is the right partner to help us achieve this vision given their global reach and commitment to bringing innovative tools to physicians and patients worldwide. We are confident this collaboration will accelerate adoption of ShortCut while continuing to advance the future of leaflet modification." The strategic investment secures an option for Medtronic to strengthen its structural heart portfolio by adding a first-of-its-kind technology that addresses a significant challenge in valve-in-valve TAVR while complementing the company's leadership in transcatheter valve therapies. It also reflects Medtronic's commitment to partnering and investing early in innovations that can improve patient outcomes, expand future treatment options, and support long-term growth. Pi-Cardia was founded by Erez Golan and Eyal Kolka, and is backed by experienced medtech investors including Sofinnova Partners, Sprig Equity, and Jacques Séguin, whose commitment has helped advance the company's vision of developing transformative leaflet modification technologies. Get curated news on YOUR industry. Enter your email to receive its newsletters.

Medtronic
Sep 2nd, 2026
Medtronic Announces Strategic Partnership with Cornerstone Robotics to Further Expand Global Access to Robotic-Assisted Surgery

Partnership expands Medtronic's robotic-assisted surgery portfolio to expand access globally and gives surgeons and health systems more choice and flexibility $700 million investment includes...

Yahoo Finance
Sep 1st, 2026
Medtronic raises revenue guidance to 7.5% after Q1 growth of 13.7%, invests $700M in Cornerstone robotics

Medtronic reported 13.7% organic revenue growth in Q1 2027, driven by strong performance across its Cardiac Rhythm Management, Cranial & Spinal Technologies, and Surgical divisions. Cardiac Ablation Solutions grew 88%, powered by Sphere-9 share gains and the Affera mapping platform, which reached $2 billion in trailing 12-month revenue. The company raised full-year organic revenue growth guidance to 7.25% to 7.75%. An extra selling week in Q1 contributed approximately $570 million to growth, a one-off benefit. Medtronic announced a $700 million strategic investment in Cornerstone's Sentire Surgical System for global robotics distribution. The company also invested in Pi-Cardia, the first FDA-cleared leaflet modification technology for transcatheter aortic valve replacement. The planned separation of its Diabetes business is expected to close before fiscal year-end, expanding operating margins by 100 basis points.

MarketScreener
Sep 1st, 2026
Medtronic lifts outlook, invests over $700 million in heart tech & Robotics - update.

Medtronic lifts outlook, invests over $700 million in heart tech & Robotics - update. Published on 09/01/2026 at 07:52 am EDT By Connor Hart Medtronic raised its outlook for the year after posting higher fiscal first-quarter profit and sales, driven by broad-based demand and contributions from newer growth platforms. The medical-device maker also announced two separate investments totaling about $780 million, one supporting a heart-technology company and the other a surgical-robotics company. Medtronic Chief Financial Officer Thierry Piéton said strong operating performance and disciplined financial management drove adjusted per-share earnings and revenue higher during the recent quarter, giving the company confidence to raise its outlook. Shares recently rose 6.5% to $96.50 in premarket trading. The company now expects full-year adjusted earnings of $5.94 to $6 a share, raising the low-end of guidance by 4 cents. Revenue is now projected to grow 7.25% to 7.75% on an organic basis, up from a prior forecast of 6.75% to 7.25%. The new outlook came as Medtronic reported net income of $1.47 billion, or $1.14 a share, up from $1.04 billion, or 81 cents a share, in last year's comparable quarter. Stripping out one-time items, earnings were $1.45 a share. Analysts polled by FactSet expected adjusted earnings of $1.39 a share. Net sales climbed 14% to $9.76 billion, topping Wall Street models for $9.55 billion. On an organic basis, sales also rose 14%. Cardiovascular sales jumped 20% to $3.93 billion, making the unit Medtronic's largest top-line contributor. Sales across the company's neuroscience arm rose 10% to $2.68 billion, while sales across its medical-surgical business gained 10% to $2.28 billion. Separately, Medtronic on Tuesday said it will invest roughly $700 million in Cornerstone Robotics in exchange for the right to distribute its Sentire surgery system in select international markets. Along with Medtronic's own Hugo robotic-assisted surgery system, the two platforms will expand access, offering surgeons and health systems more choice and flexible solutions, the company said. Medtronic also agreed to invest up to $80 million in Pi-Cardia, whose ShortCut device is the first FDA-cleared leaflet modification technology designed to enable valve-in-valve, transcatheter aortic valve replacement procedures in patients at risk of coronary obstruction The agreement also includes an option for Medtronic to acquire Pi-Cardia upon achievement of predefined milestones for an estimated upfront acquisition price of up to $210 million, the companies said. Write to Connor Hart at [email protected] (END) Dow Jones Newswires 09-01-26 0752ET (C) Dow Jones - 2026